Verici Dx plc

Equities

VRCI

GB00BM8HZD43

Medical Equipment, Supplies & Distribution

Delayed London S.E. Other stock markets 03:46:58 2024-04-30 am EDT			5-day change	1st Jan Change
7.25 ^GBX	-3.33%		-9.38%	-25.64%

Feb. 14	Verici DX raises GBP280,000 via retail offer, adding to placing raise	AN
Feb. 14	Verici Dx Raises GBP6.5 Million Via Placing, Retail Offer	MT

Verici gets ISO 27001 seal for information management security system

November 29, 2023 at 11:34 am EST

(Alliance News) - Verici Dx PLC on Wednesday said it attained the ISO 27001 certification for its information security management system.

The Cardiff, Wales-based developer of clinical diagnostics for organ transplants said ISO 27001 is an international standard specifying requirements for an ISMS.

Verici DX said conformity with the standard means that its system meets "world-wide best practice with regards to managing risks related to the security of data owned or handled by the company".

It said the certification underlines its commitment to implementing "comprehensive" security measures and ensuring the protection of sensitive data and information, reinforcing the company's position as a "trusted partner in industry and within patient care".

Verici DX said it is well-equipped to continue delivering "innovative" diagnostic solutions with ISO 27001 certification, while ensuring the highest level of protection for all sensitive information.

Shares in Verici DX were down 0.6% to 8.70 pence each in London on Wednesday late afternoon.

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Verici Dx plc

Verici DX raises GBP280,000 via retail offer, adding to placing raise	Feb. 14	AN
Verici Dx Raises GBP6.5 Million Via Placing, Retail Offer	Feb. 14	MT
EARNINGS AND TRADING: Asia Strategic loss narrows; Verici Dx grant win	Jan. 31	AN
Verici Dx plc Announces New Research Initiative	Jan. 31	CI
Verici Dx to Raise GBP280,000 via Retail Offer	Jan. 25	MT
Diversified Energy criticises "opportunistic" report	Jan. 24	AN
Verici shares fall after completing discounted GBP5.5 million placing	Jan. 24	AN
Verici Dx Proposes Placing, Conditional Retail Offer; Shares Down	Jan. 24	MT
Verici up after US health agency confirms pricing rate for blood tests	Jan. 08	AN
Verici Dx plc Announces Medicare National Payment Rate for Tutiviatm and Claravatm Effective as of January 1, 2024	Jan. 08	CI
Verici Dx hails publication of Tutivia data in transplant journal	Dec. 11	AN
Verici gets ISO 27001 seal for information management security system	Nov. 29	AN
UK inflation slowdown lifts retail and property	Nov. 15	AN
AIM WINNERS & LOSERS: Verici Dx rockets on Thermo Fisher contract	Nov. 15	AN
Verici Dx, Thermo Fisher Sign Exclusive License Deal for Pre-transplant Prognostic Testing; Shares Soar	Nov. 15	MT
Verici Dx shares jump on signing Thermo Fisher assay development deal	Nov. 15	AN
Verici Dx plc Signs Global Licensing and Commercialisation Agreement with Thermo Fisher Scientific	Nov. 15	CI
Transcript : Verici Dx plc, Q2 2023 Earnings Call, Oct 05, 2023	23-10-05
FTSE 100 Closes Up, Capping off a Positive Quarter	23-09-29	DJ
EARNINGS: Ebiquity swings to profit; SDX Energy swings to loss	23-09-29	AN
Verici Dx plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
Chapel Down sales pop; Serabi output rises	23-07-20	AN
Verici Dx plc Announces CLIA Certificate of Compliance Update US Clinical Laboratory Now Fully Accredited in 49 States	23-07-20	CI
Transcript : Verici Dx plc - Special Call	23-07-11
AIM WINNERS & LOSERS: Yourgene surges on takeover by Novacyt	23-07-03	AN

Chart Verici Dx plc

Duration

Period

More charts

Company Profile

Verici Dx plc is an immuno-diagnostics development company. The Company develops a suite of tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. Its subsidiary is Verici Dx Inc.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-09-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.075 GBP

Average target price

0.2 GBP

Spread / Average Target

+166.67%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
VERICI DX PLC	-25.64%	22.83M
BIOMÉRIEUX	+0.89%	12.95B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-7.57%	7.84B
DIASORIN S.P.A.	+2.96%	5.5B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.93%	4.61B
LANTHEUS HOLDINGS, INC.	+8.48%	4.61B
ANDON HEALTH CO., LTD.	+9.21%	2.66B
VITROLIFE AB	-13.41%	2.08B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.63%	1.72B
MYRIAD GENETICS, INC.	+3.45%	1.79B

Diagnostic & Testing Substances